1. FDA approves Lilly/Boehringer triple combo diabetes drug Trijardy XR — Pfizer misses Q4 earnings forecasts and drops early-stage programs — How insulin pricing became a top issue in the 2020 Democratic race — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Actos

Discussion in 'Ask Dr. Dave' started by Anonymous, Apr 9, 2014 at 11:28 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Opinion now please?

    from: the 5 dollar guy
     

  2. DrDave

    DrDave Member

    Joined:
    May 6, 2006
    Messages:
    557
    Likes Received:
    0
    Hey, good to hear from you!

    Unfortunately I think our original Actos exchange was deleted during a CP cleanup. In a nutshell, I will say in 2014 my feeling is that pioglitazone has a very limited role. Metformin, GLP-1s, DPP4s and probably SGLT-2 inhibitors are better choices. but, in a patient WITHOUT CHF concerns, it's probably safer than sulfonyureas.

    How about you?